Download PDF
Thromb Haemost 2012; 108(04): 623-624
DOI: 10.1160/TH12-05-0298
Pro/Contra Article
Schattauer GmbH

Contra: “Antidotes for novel anticoagulants?” – Do we really need them

Elise S. Eerenberg
*   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Marcel Levi
*   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Harry R. Buller
*   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Received: 10 May 2012

Accepted after minor revision: 25 May 2012

Publication Date:
29 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010; 103: 62-70.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Buller HR, Gallus AS, Pillion G. et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012; 379: 123-129.
    CrossrefPubMedGoogle Scholar
  • 3 Levi MM, Eerenberg E, Lowenberg E. et al. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68: 68-76.
    PubMedGoogle Scholar
  • 4 Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?. Thromb Haemost 2011; 105: 574-578.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Haverkamp D, Hutten BA, Buller HR. et al. The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolism. J Thromb Haemost 2003; 01: 69-73.
    CrossrefPubMedGoogle Scholar
  • 6 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
    CrossrefPubMedGoogle Scholar
  • 7 Crowther MA, Warkentin TE. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 2009; 07: 107-110.
    CrossrefPubMedGoogle Scholar
  • 8 Fukuda T, Honda Y, Kamisato C. et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2011; 107: 253-259.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Zhou W, Schwarting S, Illanes S. et al. Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran. Stroke 2011; 42: 3594-3599.
    CrossrefPubMedGoogle Scholar
  • 10 Levi M, Levy JH, Andersen HF. et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-1800.
    CrossrefPubMedGoogle Scholar
  • 11 Martin A, Le-Bonniec B, Lecompte T. et al. Evaluation of recombinant activated facror VII, prothrombin complex concentrate and fibrinogen concentrate to reverse apixaban in a rabbit model (presented at the ACC 2012 meeting as an oral presentation). JACC (Supplement). 2012 59. Abstract 573.
    PubMedGoogle Scholar
  • 12 Bijsterveld NR, Moons AH, Boekholdt SM. et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.
    CrossrefPubMedGoogle Scholar